

## **REMARKS**

Claims 1-37 are presently pending in the application.

The Examiner has required restriction under 35 U.S.C. § 121 to one of the following groups:

Group I. Claims 1, 2 (in part), 5-9, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 and R2 are aryl;

Group II. Claims 1, 2 (in part), 5-9, 11, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 is aryl and R2 is heteroaryl;

Group III. Claims 1, 2 (in part), 5-8, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 is heteroaryl and R2 is aryl;

Group IV. Claims 1, 2 (in part), 5-8, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 and R2 are heteroaryl;

Group V. Claims 1, 2 (in part), 5-8, 10, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 is an aryl and R2 is not a cyclic moiety;

Group VI. Claims 1, 2 (in part), 5-8, 10, 22-23 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 is a heteroaryl and R2 is not a cyclic moiety;

Group VII. Claims 1, 3, 12-14, 22, 24 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 3, where R1 is an aryl;

Group VIII. Claims 1, 3, 12, 22, 24 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 3, where R1 is a heteroaryl;

Group IX. Claims 1, 4, 15, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is O;

Group X. Claims 1, 4, 16, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is S;

Group XI. Claims 1, 4, 17, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is S(O);

Group XII. Claims 1, 4, 18, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is S(O)<sub>2</sub>;

Group XIII. Claims 1, 4, 19, 21, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is NH;

Group XIV. Claims 1, 4, 20, 22, 25 and 26-34, are drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 4, where R0 is CH<sub>2</sub>;

Group XV. Claims 35 (in part) and 36 are drawn to a method of treating or preventing ARM in a patient by administering a JNK inhibitor;

Group XVI. Claims 35 (in part) and 36 are drawn to a method of treating or preventing CNVM in a patient by administering a JNK inhibitor;


Group XVII. Claims 35 (in part) and 36 are drawn to a method of treating or preventing PED in a patient by administering a JNK inhibitor;

Group XVIII. Claims 35 (in part) and 36 are drawn to a method of treating or preventing atrophy of RPE in a patient by administering a JNK inhibitor; and

Group XIX. Claim 37 is drawn to a pharmaceutical composition comprising a JNK inhibitor.

In response, Applicants elect Group I, claims 1, 2 (in part), 5-9, 22-23 and 26-34, drawn to a method for treating or preventing MD in a patient by administering a compound according to the formula in claim 2, where R1 and R2 are aryl.

In addition, the further election of a single disclosed species is required. In response, Applicants elect without traverse 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole (*see* Specification at page 21, line 6), which has the following structure:



Applicants respectfully request that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response other than that due in connection with the Petition for Extension of Time; however, in the event that any additional fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: March 15, 2007

Respectfully submitted,

*Anthony M. Insogna, Reg. No. 35,203*  
*By: Michael J. Bruner, Reg. No. 47,458*

By: Michael J. Bruner (Reg. No. 47,458)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**

12265 El Camino Real, Suite 200

San Diego, California 92130

(858) 314-1130